&lt;p&gt;Conventional and Novel Treatment Modalities in Rosacea&lt;/p&gt;

Engın, Burhan; Özkoca, Defne; Kutlubay, Zekayi; Serdaroğlu, Server

doi:10.2147/ccid.s194074

Cited by 10 publications

(13 citation statements)

References 48 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 Hence, the development of therapeutics that address these challenges can significantly improve the treatment and care of rosacea. 16,17 Recently, an ionic liquid/deep eutectic solvent comprised of choline and geranic acid (CAGE) has been shown to exhibit characteristics that make it a potential candidate for effective treatment of rosacea. Specifically, prior in vitro studies have shown that CAGE exhibits excellent antimicrobial activity against a broad variety of pathogens 18,19 including Staphylococcus epidermidis which could be associated with pustules of rosacea.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical translation of choline and geranic acid deep eutectic solvent

Mandal²,

Dhawan

et al. 2020

Bioengineering & Transla Med

View full text Add to dashboard Cite

Choline geranate deep eutectic solvent/ionic liquid (CAGE) has shown several desirable therapeutic properties including antimicrobial activity and ability to deliver drugs transdermally in research laboratories. Here, we describe the first report of clinical translation of CAGE from the lab into the clinic for the treatment of rosacea, a common chronic inflammatory skin disorder that affects the face. We describe the seven steps of clinical translation including (a) scale-up, (b) characterization, (c) stability analysis, (d) mechanism of action, (e) dose determination, (f) GLP toxicity study, and (g) human clinical study. We describe the challenges and outcomes in these steps, especially those that uniquely arise from the deep eutectic nature of CAGE. Our translational efforts led to a 12-week open-label phase 1b cosmetic study with CAGE 1:2 gel (CGB400) in mild-moderate facial rosacea in 26 patients where CGB400 exhibited a marked reduction in the number of inflammatory lesions. These results demonstrate the therapeutic potential of CGB400 for treating rosacea as well as it provides insights into the translational journey of deep eutectic solvents, in particular CAGE, for dermatological applications.

show abstract

Section: Introductionmentioning

confidence: 99%

“…They are also limited by treatment cost, poor dermal permeation, and have certain regional restrictions of manufacturing 15 . Hence, the development of therapeutics that address these challenges can significantly improve the treatment and care of rosacea 16,17 …”

Section: Introductionmentioning

confidence: 99%

Clinical translation of choline and geranic acid deep eutectic solvent

Mandal²,

Dhawan

et al. 2020

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…6 A variety of treatment modalities have been reviewed, including skin care and cosmetic treatments, topical therapies, oral therapies, laser-and light-based therapies, injection therapies, and combination therapies, based on their anti-demodex, anti-inflammatory, and anti-angiogenesis effects. [36][37][38][39] However, recalcitrant, refractory, and persistent rosacea remains challenging in rosacea treatment. 12,40 Botulinum toxin, especially type A, has many off-label uses in aesthetic treatments.…”

Section: Discussionmentioning

confidence: 99%

Use of Botulinum Toxin in Treating Rosacea: A Systematic Review

Zhang

Tang

Wang

et al. 2021

CCID

View full text Add to dashboard Cite

Background Rosacea is a chronic skin disorder characterized by erythema, flushing, telangiectasia, papules and pustules, phymatous changes, and ocular involvement. The aim of this study was to examine all published research articles in which botulinum toxin was used to treat rosacea and to evaluate the efficacy and safety of this treatment. Methods PubMed, Embase, Cochrane Library, and Web of Science database were used to identify articles eligible for systematic review on March 26, 2021. Prospective or retrospective studies which directly used botulinum toxin to treat rosacea were included and reviewed. Results Nine studies were included in this systematic review. Two were randomized controlled trials, graded as Level 2 for the quality of evidence. The total number of participants was 130, and the number of participants in each study ranged from 1 to 25. The improvement was observed in all studies in signs and symptoms compared with baseline. Adverse events were transitory and self-limited. Conclusion Botulinum toxin could have overall satisfying efficacy and safety in the treatment of rosacea, though limited by small sample size, imperfect study design, and short follow-up visits.

show abstract

“…It has a significant negative effect on the quality of life and is a risk factor for depression and anxiety. [1,2] The main symptoms of rosacea are erythema, telangiectasia, edema, papules, pustules, stinging, and hot flushes. Recently, the international prevalence of rosacea was reported to be approximately 5.5%.…”

Section: Introductionmentioning

confidence: 99%

Elucidating the potential pharmaceutical mechanism of Gyejibokryeong-hwan on rosacea using network analysis

Kim

2023

Medicine

View full text Add to dashboard Cite

Rosacea is a chronic erythematous disease with telangiectasia that affects the central area of the face. However, because of the ambiguity in the pathophysiology of rosacea, its treatment has not been clearly elucidated; therefore, new therapeutic options need to be developed. Gyejibokryeong-hwan (GBH) is widely used in clinical practice for various blood circulation disorders, including hot flushes. Therefore, we explored the potential pharmaceutical mechanism of GBH on rosacea and investigated the therapeutic points exclusive to GBH through comparative analysis with chemical drugs recommended in 4 guidelines for rosacea based on network analysis. The active compounds in GBH were identified, and the proteins targeted by these compounds and the genes related to rosacea were searched. Additionally, the proteins targeted by the guideline drugs were also searched to compare their effects. And the pathway/term analysis of common genes was conducted. Ten active compounds were obtained for rosacea. There were 14 rosacea-related genes targeted by GBH, with VEGFA, TNF, and IL-4, which were suggested as core genes. The pathway/term analysis of the 14 common genes revealed that GBH could potentially act on rosacea via 2 pathways: the "interleukin 17 signaling pathway" and the "neuroinflammatory response." Comparison and analysis of the protein targets between GBH and guideline drugs revealed that only GBH separately acts on the "vascular wound healing pathway." GBH has the potential to act on IL-17 signaling pathway, neuroinflammatory response and vascular wound healing pathway. Further studies are needed to determine the potential mechanism of GBH in rosacea.Abbreviations: DL = drug-likeness, GBH = Gyejibokryeong-hwan, GO = gene ontology, IL = interleukin, KEGG = Kyoto encyclopedia of genes and genomes, MMP = matrix metalloproteinase, NF = nuclear factor, NK = natural killer, OB = oral bioavailability, PPI = protein-protein interaction, TCMSP = traditional Chinese medicine systems pharmacology database and analysis platform, TNF = tumor necrosis factor, TRP = transient receptor potential, UV = ultraviolet, VEGFA = vascular endothelial growth factor A.

show abstract

<p>Conventional and Novel Treatment Modalities in Rosacea</p>

Cited by 10 publications

References 48 publications

Clinical translation of choline and geranic acid deep eutectic solvent

Clinical translation of choline and geranic acid deep eutectic solvent

Use of Botulinum Toxin in Treating Rosacea: A Systematic Review

Elucidating the potential pharmaceutical mechanism of Gyejibokryeong-hwan on rosacea using network analysis

Contact Info

Product

Resources

About